Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal bone lossa PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Oczakir et al. [6] 2005 CS 1/4 pSS 0/1 24 100% (1/1)
100% (4/4) 		100% (1/1)
100% (2/2) 		NR 0% (0/1)
0% (0/4) 		NR
1/8 sSS+SSc 0/1 60 100% (1/1)
100% (8/8) 		100% (1/1)
100% (2/2) 		NR 0% (0/1)
0% (0/8) 		NR
Petsinis et al. [7] 2017 RS 2/7 SS (type NR)b 0/2 Mean: 110 100% (2/2)
100% (7/7) 		100% (2/2)
NR 		NR 0% (0/2)
0% (0/7) 		NR
Isidor et al. [14] 1999 PS 8/54 sSS+RA, sSS+SSc 0/8 48 50% (4/8)
87% (45/54)
Early loss: 7
Late loss: 2 		100% (8/8)
100% (11/11) 		Mean: 0.74 NR NR
Binon [34] 2005 CR 1/6 sSS+RA 1/0 156 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		NR NR NR
In 't Veld et al. [45] 2022 CR 1/4 SS (type NR) 0/1 2 100% (1/1)
100% (4/4) 		100% (1/1)
100% (1/1) 		NR NR NR
Mori et al. [53] 2018 CR 1/8 pSS 0/1 36 100% (1/1)
100% (8/8) 		100% (1/1)
100% (4/4) 		0 0% (0/1)
0% (0/8) 		NR
Nam et al. [55] 2012 CR 1/14 sSS+SSc 0/1 4 100% (1/1)
100% (14/14)d 		Irr. NR NR NR
Peron et al. [58] 2017 CR 1/5 sSS+RA 0/1 36 100% (1/1)
100% (5/5) 		NR 0 NR NR
Spinato et al. [61] 2010 CR 1/6 pSS 0/1 12 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		0 NR NR
Chochlidakis et al. [65] 2016 CR 1/6 sSS+SLE+HT 0/1 14 100% (1/1)
100% (6/6) 		100% (1/1)
100% (2/2) 		NR NR NR
de Mendonça Invernici et al. [66] 2014 CR 1/2 sSS+RA 0/1 72 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 NR NR
Krennmair et al. [71] 2010 RS 8/39 sSS+RA, sSS+RA+SSc 0/8 Mean: 51.9 100% (8/8)
100% (39/39) 		100% (8/8)
100% (9/9) 		NR NR NR
Siddiqui et al. [73] 2017 RS 11/23 SS (type NR) NR 40 81.8% (9/11)
87% (20/23)
Early loss: 3
Late loss: 0 		NR NR NR NR
Chatzistavrianou et al. [78] 2016 CS 1/2 pSS 0/1 24 100% (1/1)
100% (2/2) 		NR NR NR NR
1/8 sSS (concomitant CTD NR) 0/1 18 100% (1/1)
100% (8/8) 		NR NR NR NR
Chrcanovic et al. [79] 2019 CS 19/107 SS (type NR) 1/18 Mean: 125.5 89.5% (17/19)
97.2% (104/107)
Early loss: 2
Late loss: 1 		NR Mean: 2.19 NR NR
Esposito et al. [80] 2003 CS 1/2 pSS+OLP 0/1 18 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 0% (0/1)
0% (0/2) 		100% (1/1)
100% (2/2)e
Payne et al. [81] 1997 CS 1/6 pSS 0/1 12 100% (1/1)
100% (6/6) 		100% (1/1)
100% (1/1) 		NR NR NR
2/20 sSS+RA, sSS+ST 0/2 Mean: 54 50% (1/2)
85% (17/20)
Early loss: 2
Late loss: 1 		100% (2/2)
100% (4/4) 		NR NR NR
Corigliano et al. [83] 2014 CS 2/13 pSS,
SS (type NR) 		0/2 Mean: 27 100% (2/2)
100% (13/13) 		100% (2/2)
100% (3/3) 		NR 0% (0/1). NR: 1
0% (0/2). NR: 11 		NR
Alenazi [84] 2021 CCS 4/NR sSS+RA NR Mean: 44.6c 100% (4/4)
NR 		100% (4/4)
NR 		NR NR NR
14/39 Control group 7/7 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR
Korfage et al. [87] 2016 CCS 50/140 pSS,
sSS (concomitant CTD NR) 		4/46 Median: 46 96% (48/50)
97.1% (136/140)
Early loss: 4
Late loss: 0 		NR Median: 0.89 14% (7/50)
11.4% (16/140) 		NR
50/125 Control group 4/46 Median: 45.6 100% (50/50)
100% (125/125) 		NR Median: 0.66 12% (6/50)
8.8% (11/125) 		NR
Overall
SS - CR: 8
CS: 6
RS: 3
CCS: 2
PS: 1 		120/484 - Ratio: 1/16.5 Mean: 68.1
Median: 46 		90.8% (109/120)
95.5% (462/484)
Of these: 81.8% (18/22) early loss 		100% (36/36)
100% (43/43) 		Mean: 1.49
Median: 0.89 		12.3% (7/57)
9.4% (16/171) 		100% (1/1)
100% (2/2)e
SS+
concomitant ADs 		- CR: 5
CS: 4
CCS: 1
PS: 1
RS: 1 		30/164 - Ratio: 1/25 Mean: 49.4 83.3% (25/30)
92.7% (152/164)
Of these: 75% (9/12) early loss 		100% (27/27)
100% (31/31) 		Mean: 0.63 0% (0/2)
0% (0/10) 		100% (1/1)
100% (2/2)e
Control group - CCS: 2 64/164 - Ratio: 1/4.8 Mean: 39.4
Median: 45.6 		100% (64/64)
100% (164/164) 		100% (14/14)
NR 		Median: 0.66 12% (6/50)
8.8% (11/125) 		NR

a = weighted mean or median; b = remission at implant placement; c = reported for RA+CTDs but NR specific for sSS; d = late loss NR; e = criteria by Esposito et al. [26].
ADs = autoimmune diseases; CCS = case-control study; CR = case report; CS = case series; CTDs = connective tissue diseases; HT = hypothyroidism; Irr. = irrelevant; M/F = male/female; N = number; NR = not reported; OLP = oral lichen planus; PI = peri-implantitis; PS = prospective study; pSS = primary Sjögren's syndrome; RA = rheumatoid arthritis; RS = retrospective study; SLE = systemic lupus erythematosus; SSc = systemic scleroderma; sSS = secondary Sjögren's syndrome; ST = Still's disease.